FDA hands a ‘break­through’ des­ig­na­tion to Seat­tle Ge­net­ics’ piv­otal-stage can­cer drug en­for­tum­ab

Seat­tle Ge­net­ics and their part­ners at Astel­las got a boost from the FDA to­day for their quest to score an ac­cel­er­at­ed ap­proval for en­for­tum­ab ve­dotin.

The agency has stamped their break­through drug des­ig­na­tion on the pro­gram, high­light­ing its po­ten­tial as the drug makes its way through a piv­otal Phase II study for metasta­t­ic urothe­lial can­cer. That’s a wel­come en­dorse­ment for Seat­tle Ge­net­ics $SGEN, which has tapped this drug as one of its top clin­i­cal prospects.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.